EXOME

all the information, none of the junk | biotech • healthcare • life sciences

Avalon’s aFraxis Raises $750K

San Diego’s aFraxis has raised $750,000 in early stage funding, according to a recent regulatory filing submitted to the Securities and Exchange Commission. The startup backed by San Diego’s Avalon Ventures was founded in 2007, and is focused on developing treatments for Fragile X syndrome and autism. Avalon’s Jay Lichter is listed as chief executive and  director. A newsletter published by the Massachusetts-based Fraxa Research Foundation has reported that aFraxis is exploring a treatment strategy identified by Susumu Tonegawa, a Nobel laureate and MIT professor of biology and neuroscience.